Amgen seeks FDA OK for once-a-month dose of Repatha; Greece lifts ban on drugs exports;

@FiercePharma: USDA, poultry producers warn MN officials to expect bird flu resurgenceFierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article | Follow @EricPFierce

@CarlyHFierce: This date last year, I saved a story on my computer as "GSK Woes." So basically, not much has changed. | Follow @CarlyHFierce

> Greece has lifted its ban on drug exports, put in place when its fiscal woes led some to believe that drug shortages could arise. Story

> Amgen ($AMGN) has filed with the FDA for approval of a single once-per-month 420 mg injection of its new cholesterol fighter Repatha (evolocumab), which currently is available in a single-use 140 mg/mL prefilled autoinjector that requires three subcutaneous injections for a dose of 420 mg. Report

> Eli Lilly ($LLY) is expanding its new innovation center in Cambridge, MA. Story

> Allergan ($AGN) and Perrigo ($PRGO) have gotten approval for their copies of three Mucinex products. Release

Medical Device News

@FierceMedDev: ShiftLab's first device is nearing commercialization. Will it start a low-cost revolution? More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Robotic surgery aspirant receives $4M+ in equity financing. Article | Follow @VarunSaxena2

@EmilyWFierce: JAMA: Women face increased risk for second vaginal mesh surgery 10 years after implant. Article | Follow @EmilyWFierce

> Startup Velico nabs another $15.5M from BARDA for dried plasma tech. Story

> Nipro to buy partner, heart attack prediction imaging upstart Infraredx. Report

> WSJ: Feds to launch power morcellator probe aimed at FDA. Article

Biotech News

@FierceBiotech: FierceBiotech radio on GSK's latest setback, Kyle Bass' 'truthful irrelevancy,' and Horizon's web presence. More | Follow @FierceBiotech

@JohnCFierce: Four years after a transatlantic slapdown, Merck KGaA will once again seek cladribine OK. Article | Follow @JohnCFierce

@DamianFierce: I hereby endorse this bold, disruptive approach to the language of innovation. More | Follow @DamianFierce

> Lilly upsizes its new Cambridge, MA, R&D shop as Big Pharma crowds the neighborhood. Report

> Soon-Shiong's NantCell hauls in another $100M for immuno-oncology R&D. Story

> FDA advisers side against Purdue's new painkiller, citing dosing dangers. Article